(1-trityl-1H-benzimidazol-5-yl)methanol | 239482-69-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (1-trityl-1H-benzimidazol-5-yl)methanol
• 英文别名: 1-Trityl-1H-benzimidazol-5-yl-methanol；(1-tritylbenzimidazol-5-yl)methanol
• CAS: 239482-69-0
• 化学式: C₂₇H₂₂N₂O
• 分子量: 390.484
• InChiKey: ADEFEGMEGJKZSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1-trityl-1H-benzimidazol-5-yl)methanol 在 palladium on activated charcoal 氯化亚砜 、 sodium azide 、 氢气 作用下， 以 甲醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (1-Tritylbenzimidazol-5-yl)methanamine
  参考文献：
  名称：

  Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues

  摘要：

  Peptidomimetic inhibitors of thrombin lacking the important Ser195-carbonyl interaction have been prepared. The binding energy lost after the removal of the activated carbonyl was recaptured through a series of modifications of the PI residues of the bicyclic lactam inhibitors. Selected substituted compounds displayed useful pharmacological profiles both in vitro and in vivo. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00661-8
• 作为产物：
  描述：

  1H-苯并咪唑-5-羧酸 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 TEA 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (1-trityl-1H-benzimidazol-5-yl)methanol
  参考文献：
  名称：

  Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues

  摘要：

  Peptidomimetic inhibitors of thrombin lacking the important Ser195-carbonyl interaction have been prepared. The binding energy lost after the removal of the activated carbonyl was recaptured through a series of modifications of the PI residues of the bicyclic lactam inhibitors. Selected substituted compounds displayed useful pharmacological profiles both in vitro and in vivo. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00661-8

文献信息

• Novel benzophenone derivatives or salts thereof
  申请人：Chaki Hisaaki

  公开号：US20050113400A1

  公开（公告）日：2005-05-26

  A benzophenone derivative represented by the following formula: wherein R 1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R 2 represents, for example, a carboxyl group optionally protected with alkyl; R 3 represents, for example, an optionally protected hydroxyl group; R 4 represents, for example, an optionally substituted cycloalkyloxy group; and R 5 represents, for example, a hydrogen atom, or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.

  以下是一种苯甲酮衍生物的化学式： 其中，R1代表例如可选取代的杂环基团或取代的苯基团；Z代表例如烷基链；R2代表例如可用烷基保护的羧基；R3代表例如可选保护的羟基；R4代表例如可选取代的环烷氧基团；R5代表例如氢原子或其盐。该化合物具有抗关节炎活性，能抑制由关节炎引起的骨破坏，并提供高安全性和优异的药代动力学，因此可用作治疗关节炎的药物。这些化合物具有抑制AP-1活性的作用，可用作预防或治疗与过度表达AP-1有关的疾病的药物。
• Histamine H3 receptor ligands
  申请人：Kalindjian Sarkis Barret

  公开号：US06878736B1

  公开（公告）日：2005-04-12

  Compounds of formula (I) (and pharmaceutically acceptable salts thereof) are histamine H 3 receptor ligands. A in the formula represents (CH 2 ) m , m being from 1 to 3; B is (CH 2 ) n , n being from 1 to 3; x is from 0 to 2; R 1 is C 1 to C 10 hydrocarbyl, in which up to 2 carbon atoms may be replaced by O, S or N; and up to 2 hydrogen atoms may be replaced by halogen; R 2 is H or C 1 to C 15 hydrocarbyl, in which up to 3 carbon atoms may be replaced by O, S or N, and up to 3 hydrogen atoms may be replaced by halogen; R 3 is absent when —Y—Z—R 2 is attached to W, or is H or C 1 to C 7 hydrocarbyl when —Y—Z—R 2 is not attached to W; W is nitrogen; X is —CH 2 —, —O— or —NR 4 —, R 4 being H or C 1 to C 3 alkyl; Y replaces a hydrogen atom on any of A, B, W and X, and is C 2 to C 10 alkylene, in which one non-terminal carbon atom may be replaced by O; and Z is (II), (III), (IV), (V), (VI), or (VII) wherein R 5 , R 6 and R 7 are independently H or C 1 to C 15 hydrocarbyl, in which up to 3 carbon atoms may be replaced by O or N, and up to 3 hydrogen atoms may be replaced by halogen, and Q is H or methyl, or Q is linked to R 5 or R 7 to form a five-membered ring or Q is linked to R 2 to form a six-membered ring

  公式（I）的化合物（及其药学上可接受的盐）是组胺H3受体配体。 公式中的A代表（CH2）m，其中m为1至3; B为（CH2）n，其中n为1至3; x为0至2; R1为C1至C10烃基，其中最多可有2个碳原子被O，S或N取代; 最多可将2个氢原子替换为卤素; R2为H或C1至C15烃基，其中最多可有3个碳原子被O，S或N取代，最多可将3个氢原子替换为卤素; 当-Y-Z-R2连接到W时，R3不存在，或当-Y-Z-R2未连接到W时，R3为H或C1至C7烃基; W为氮; X为—CH2—，—O—或—NR4—，其中R4为H或C1至C3烷基; Y替换A，B，W和X中的任何一个氢原子，为C2至C10的烷基，其中一个非端碳原子可被O取代; Z为（II），（III），（IV），（V），（VI）或（VII），其中R5，R6和R7独立地为H或C1至C15烃基，其中最多可有3个碳原子被O或N取代，最多可将3个氢原子替换为卤素，Q为H或甲基，或Q与R5或R7连接形成五元环，或Q与R2连接形成六元环。
• HISTAMINE H3 RECEPTOR LIGANDS
  申请人：JAMES BLACK FOUNDATION LIMITED

  公开号：EP1056733B1

  公开（公告）日：2004-01-07
• NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF
  申请人：TOYAMA CHEMICAL CO., LTD.

  公开号：EP1445249B1

  公开（公告）日：2012-11-07
• US6878736B1
  申请人：——

  公开号：US6878736B1

  公开（公告）日：2005-04-12